Mustang Bio, Inc. (MBIO)

Market Cap	5.08M -2.4%
Revenue (ttm)	n/a
Net Income	-2.72M
EPS	-0.46
Shares Out	7.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,028,538
Open	0.6900
Previous Close	0.6900
Day's Range	0.6700 - 0.7792
52-Week Range	0.5306 - 7.0000
Beta	2.08
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: MBIO
• Website: https://www.mustangbio.com